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Cutoff criteria for the placebo 
response: a cluster and machine 
learning analysis of placebo 
analgesia
Per M. Aslaksen
Computations of placebo effects are essential in randomized controlled trials (RCTs) for separating 
the specific effects of treatments from unspecific effects associated with the therapeutic intervention. 
Thus, the identification of placebo responders is important for testing the efficacy of treatments and 
drugs. The present study uses data from an experimental study on placebo analgesia to suggest a 
statistical procedure to separate placebo responders from nonresponders and suggests cutoff values 
for when responses to placebo treatment are large enough to be separated from reported symptom 
changes in a no-treatment condition. Unsupervised cluster analysis was used to classify responders 
and nonresponders, and logistic regression implemented in machine learning was used to obtain 
cutoff values for placebo analgesic responses. The results showed that placebo responders can be 
statistically separated from nonresponders by cluster analysis and machine learning classification, and 
this procedure is potentially useful in other fields for the identification of responders to a treatment.
The use of placebos is crucial in medical science to determine the effects and efficacy of  treatments1,2. Because 
randomized controlled trials (RCTs) use placebo conditions as a control, the definition of placebo responders is 
important to make valid statements about the statistical effects of  treatments3. However, there is no consensus 
on how to statistically define a placebo responder or how to determine the cutoff for when a placebo response is 
large enough to be considered a true change from baseline. The majority of studies investigating the mechanistic 
components of the placebo response have used the placebo response in the context of pain, i.e., placebo analgesia, 
as the modality for studying this  effect4.
Experimental studies on the mechanisms of the placebo response have traditionally relied on defining a pla-
cebo effect as the statistically significant difference in mean values between a group that receive placebo treatment 
and a group that receive no treatment but undergo the same assessments and procedures as the placebo  group5. 
However, statistically significant differences are largely dependent on sample sizes, and larger samples might 
produce significant differences between groups that may have no practical or clinical  relevance6. In the field of 
clinical pain, several authors have previously addressed this issue, and values for minimal clinically important 
differences in pain change have been suggested in terms of absolute changes and percentage changes. In a study 
on acute pain in trauma patients, Todd et al.7 found that an absolute pain reduction of 13 mm on a 100-mm 
visual analog scale (VAS) was a valid cutoff value for a clinically significant change in acute pain. The finding by 
Todd et al. was replicated in other  studies8,9, but there was the notion that patients with higher pain at baseline 
required a higher VAS reduction compared to those with lower initial VAS ratings to achieve a meaningful 
reduction in  pain9. The relative percentage change in pain might in some situations be less biased by baseline 
or pretreatment pain compared to the absolute VAS change, and Jensen et al.10 suggested that more than a 33% 
relative and 20–30 mm absolute reduction in individual VAS scores constituted a clinically meaningful change 
in postoperative pain. In a study employing meta-regression on data from 10,938 patients from 40 studies with 
various diagnoses of chronic pain, a minimum clinically important difference of 28 mm on the 100-mm VAS 
scale was  found11. Thus, the cutoff values for a clinically relevant VAS change vary among acute, postoperative, 
and chronic types of pain.
However, most mechanistic studies on placebo analgesia have been performed in healthy volunteers who 
had no prior history of long-lasting pain. Thus, the most comparable clinical category is probably acute pain. By 
using the cutoff value from Todd et al.7, a meta-analysis on placebo  effects12 found that only 26% of the included 
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placebo studies performed in healthy volunteers reported clinically significant pain reduction after placebo 
treatment. Minor pain reductions in placebo analgesic studies could be problematic for the interpretation and 
generalizability of mechanistic studies on the placebo response. Furthermore, the reported response rate to 
placebo treatment varies substantially between studies and between experimental and clinical  settings13,14. In 
an influential and debated study by  Beecher15, the response rate to placebo in clinical pain was estimated to be 
35.2%, whereas other more recent studies have shown values between 39–78%16,17 and a 56–72% response rate 
for experimental placebo  analgesia18,19 when a responder was defined as a participant who reported a change in 
pain in the expected direction after placebo treatment. Hence, the majority of studies reporting the percentage of 
placebo responders define a placebo responder as a patient or a participant in an experimental study that reports 
any pain reduction measured on a VAS or numerical rating scale (NRS) after placebo treatment, regardless of 
the magnitude of the pain  reduction12.
Here, data from a large experimental placebo analgesic study performed in healthy  volunteers20 were used 
to test the assumption that placebo responders can be separated from nonresponders by cutoff values for both 
absolute and relative percentage changes in pain measured on a 100-mm VAS. Data from 296 participants (179 
females) were included. Thermal pain stimulation was performed in two pretests and three posttests, and the 
temperature for pain stimulation needed to evoke a rating of 60 on a 100-mm computerized visual analog scale 
was individually determined for each participant in a calibration phase before the pretests. Placebo administra-
tion (placebo cream) together with information that the cream was a painkiller was performed after the pretests. 
The design consisted of a double-blind procedure in the placebo group, whereas the control group received no 
cream but experienced the same pain procedure as the placebo group.
Unsupervised cluster analysis was used to classify responders and nonresponders, and the classification was 
tested with different cutoffs in a supervised machine learning algorithm based on logistic regression. If a placebo 
analgesic manipulation produces either responders or nonresponders, an unsupervised cluster analysis should 
result in two clusters. Since placebo analgesia is dependent on a reduction in pain reports measured on the same 
scales as clinical pain, it was hypothesized that reductions in pain after placebo treatment should have the same 
magnitude as pain reduction after clinical  treatment7,10,11 to refer to the response as “analgesia”. Consistent with 
the predictions, the cluster analysis revealed two distinct clusters in the data separated by significant differences 
in pain change after placebo treatment. Furthermore, the machine learning classification suggested cutoff values 
for placebo analgesic responses close to the suggested cutoffs for acute clinical pain. The assumption that pain 
reporting after placebo administration results in a two-cluster solution was supported by testing pain change 
data from three previously published studies from our  lab21–23. Consequently, it is suggested that the statistical 
approach in the present study could be used as an alternative for defining placebo responders in both clinical 
and experimental studies where patient self-report is the main outcome.
Results
Group differences. A comparison of pretest and posttest values in the placebo group showed a significant 
mean decrease in pain intensity of 16.76 VAS points (95% CI [13.94–19.59]) after placebo manipulations con-
sisting of verbal information and application of a placebo cream (t (145) = 11.72, p < .001). The mean values of 
the two pretests were 58.24 (95% CI [55.67–61.11]), and the mean pain intensity in the posttest was 41.48 VAS 
points (95% CI [38.39–45.02]) on the 100-mm VAS scale. In contrast, in the control group that received no 
manipulations during the pain stimulation procedure, the mean decrease in pain was significant (t (124) = 3.04, 
p = .003), with a 3.26 VAS points reduction (95% CI [1.03–5.39]) from the pretest to the posttest. When compar-
ing the placebo group and the control group, a significantly larger pain reduction was observed in the placebo 
group (t (294) =  − 7.85, p < .001). Hence, the design produced a statistically significant placebo analgesic effect.
Cluster analysis. A two-step unsupervised cluster analysis was performed on the VAS change scores for 
the mean of the two pretests and the last posttest (pretests–last posttest). Before performing the two-step cluster 
analysis, the order of the participants in the data file was randomized in order to reduce order-effects. In the 
placebo group, the analysis revealed two distinct clusters (Fig. 1) with means of 32.68 (95% CI [30.43–34.91]) 
Figure 1.  Box and violin plots showing the density of placebo responders versus nonresponders.
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and 5.16 (95% CI [2.98–7.33]), medians of 31 and 7.5, and modes of 29.5 and 3 for changes in VAS pain ratings. 
The cluster quality was good, with an average silhouette measure of .7. The two clusters were termed placebo 
responders (N = 65, 42%) and nonresponders (n = 90, 58%), respectively. The distribution of changes in pain 
for the responders and nonresponders is shown in Fig. 2, and the mean difference in pain changes between the 
responders and nonresponders was significant (t (153) = 17.19, p < .001). The effect size was very  large24 based on 
the mean difference between the responders and the nonresponders (32.68–5.16/SD 16.70 = 1.65; Cohen’s d). To 
test the stability of the results from the two-step cluster analysis, the order of the sample was randomized again 
and split into halves and then run in two separate samples. When splitting the sample, the results were identical 
to the initial analysis with two clusters and a silhouette measure of .7. The cluster solution with two clusters was 
additionally tested in a supervised k-means cluster analysis. The k-means analysis showed that a two-cluster 
solution produced the same number of responders (N = 65), and nonresponders (N = 90), the two clusters had 
final cluster centers of 32.68 and 4.88, and the ANOVA test for differences in cluster means was significant (F (1, 
153) = 295.54, p < .001).
When performing the two-step cluster analytic procedure on data from the control group, four clusters 
emerged with good quality of the clusters (.7) determined by the average silhouette measure (cluster 1, N = 23, 
mean = 20.8; cluster 2, N = 42, mean = 8.83; cluster 3, N = 50, mean =  − .09; cluster 4, N = 26, mean =  − 13.13).
Validation of the two-cluster solution for placebo responding. The unsupervised cluster analysis 
for classification was additionally tested on data from the placebo arms and/or conditions in published studies 
with smaller samples from our  lab21–23. The two-step cluster analysis classified the pain change data in two-
cluster solutions in all three datasets, with silhouette measures .7, .7, and .6, respectively. Thus, the classification 
produced cluster solutions of good quality, and the assumption that self-reported responses after placebo admin-
istration can be classified in responders and non-responders was supported. See Supplemental information for 
details about the validation of the cluster solution.
Determination of cutoff values by machine learning. The two categories (placebo responders and 
nonresponders) derived from the cluster analysis in the placebo group were used as dependent variables in a 
machine learning algorithm based on logistic regression. Values for pain change ranging from 0 to 50 for per-
centage change and change values from 0 to 25 for absolute VAS change were tested as possible cutoff values. 
The false discovery rate (FDR) was used to assess the predictive ability for each of the selected cutoff values, and 
q ≤ 5% was chosen as the FDR criterion for a valid cutoff that could separate responders from nonresponders. 
The optimal cutoff values (Table 1) for a VAS change were 18–20. These values produced identical area under the 
curve (AUC) values (.99) and showed high accuracy (99.4%) for the prediction of the placebo responders identi-
fied by the cluster analysis. Furthermore, low (0–1%) FDR values for both false classification of responders and 
nonresponders suggested a highly precise prediction. A VAS change value of 17 also reached the FDR criterion 
but with somewhat lower AUC and accuracy values. In summary, absolute VAS changes in the range between 
17 and 20 points could separate responders from nonresponders within the 5% FDR criterion. In comparison, a 
cutoff based on any or a small change in pain (≥ 0) showed a predictive value close to chance level (AUC = .61), 
whereas a cutoff based on a large VAS change score (≥ 25) correctly classified all the nonresponders but incor-
rectly classified 17% of the responders as nonresponders. Thus, using higher cutoff values may increase the false 
negative rate. When using different cutoffs for percentage change values (0 to 50% change in VAS ratings), the 
optimal cutoffs were 27–28% change (AUC = .99, accuracy = 99.3%) with FDR values of 0–1% (Table 1). Percent-
age changes between 25 and 30 all passed the 5% FDR criterion but with lower AUC (.96–.97) and accuracy 
values (97.3–97.9%). Calculation of the Youden  index25 was additionally performed to compare cutoffs from the 
logistic machine learning analysis with a widely used method for this  purpose26. Generally, the machine learning 
procedure and the Youden method gave similar cutoff values (see Table 1).
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Discussion
The gold standard for the determination of a placebo effect in experimental designs is the observation of statisti-
cally significant differences between one or more groups receiving placebo treatment and a group receiving the 
same procedure but with no  treatment27. Hence, this definition is based on observed differences in measures 
of central tendencies, most often mean differences, regardless of the magnitude of the change; when statistical 
significance is used as the only criterion, this might not account for the physiological and psychological experi-
ence of the stimulation or whether analgesia is induced.
The results from the present study and studies on cutoffs for clinical  pain7–11 suggest that small, albeit statisti-
cally significant, changes in pain after treatment may have no practical or clinical relevance. Furthermore, when 
using any pain change in the desired direction as the definition of placebo responders, the present data showed 
that the accuracy was close to chance. This is a problem for the interpretation of experimental studies on placebo 
analgesia with no criterion for defining when changes in pain magnitude are sufficient to be considered meaning-
ful decreases in pain perception. However, studies with small but significant changes in pain may still provide 
important information about mechanisms of placebo-induced changes in physiological systems related to pain 
 perception21,28 and how contextual and psychological factors associated with placebo administration may affect 
treatment or experimental outcomes;  see2,29,30 for an overview. Nonetheless, the term “analgesia” refers to the relief 
of pain without the loss of consciousness, and studies making inferences about placebo analgesia should at least 
display changes in pain ratings large enough to be recognized as reduced pain intensity that are perceived as such.
The results from the present study showed a significant difference in mean pain change between the placebo 
group and the control group. Nonetheless, the cluster analysis revealed that one of the clusters in the control 
Table 1.  Cutoff values from logistic regression machine learning. The VAS absolute change is the absolute 
change in VAS pain intensity ratings from the pretests to the posttest. The VAS percent change is the 
percentage change in VAS pain intensity ratings from the pretests to the posttest. Bold type indicates q ≤ 5%. 
VAS visual analog scale, AUC area under the curve, FDR false-discovery rate.
VAS absolute change AUC Accuracy % FDR responder % FDR non-responder % Youden index
0 .61 55.5 52 36 .27
5 .66 65.8 45 0 .40
10 .79 78.7 33 0 .62
15 .9 91 18 0 .83
16 .95 95.5 10 0 .91
17 .98 98.7 3 0 .97
18 .99 99.4 1 0 .98
19 .99 99.4 0 1 1.0
20 .99 99.4 0 1 1.0
21 .94 96.8 0 5 .94
22 .92 95.5 0 7 .91
23 .9 94.2 0 9 .88
24 .86 91.6 0 13 .82
25 .84 88.4 0 17 .74
VAS % change AUC Accuracy % FDR responder % FDR non-responder % Youden index
0 .64 69.2 36 0 .29
5 .69 74 32 0 .38
10 .77 80.1 27 0 .50
15 .83 86 20 0 .62
20 .91 92.5 12 0 .74
25 .96 97.3 5 0 .88
26 .97 97.9 4 0 .89
27 .99 99.3 1 0 .93
28 .99 99.3 0 1 .96
29 .97 97.9 0 4 .94
30 .97 97.9 0 4 .95
31 .96 97.3 0 6 .95
32 .94 95.9 0 8 .92
33 .93 93.8 0 12 .89
34 .9 91.8 0 15 .85
35 .89 91.1 0 16 .84
40 .84 84.9 0 25 .72
45 .81 81.5 0 29 .66
50 .72 72.6 0 37 .49
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group data had a pain reduction that could be classified as placebo responses according to the cutoff values found 
in the present study if it had been observed in the placebo group. Moreover, the second cluster in the control 
group had a mean pain change of 8.83, which is comparable to placebo induced pain changes in several previous 
 studies5,12,31,32. These findings suggests that relatively large changes in experimental pain reports could occur in 
the absence of a treatment and be caused by factors such as reporting biases, individual differences in emotional 
responses to the pain stimulation, and statistical regression to the  mean33–35. Thus, the possibility exist that parts 
of the improvement observed in the placebo group would also have occurred without the placebo  treatment36.
The present study is probably the first to provide cutoff values for experimental placebo analgesia. The optimal 
cutoff values of 18–20 mm for absolute VAS changes and 27–28% changes are not surprising given findings in 
studies on clinical  pain7–11. However, the cutoff suggested by Todd et al.7 of a 13-mm change for acute pain was 
too liberal in the present data, as shown by both the machine learning analysis and the Youden index.
Nonetheless, the cutoffs found in the present study were based on a specific procedure for placebo treatment 
and pain stimulation, and different procedures might provide different values. A limitation of the present data 
is that the pain measurement did not include a qualitative measure for rating the perceived  pain37 after placebo 
treatment as “much less", "little less", "the same", etc. Hence, minimally clinically important difference (MCID) 
values could not be computed. On the other hand, the present results are in line with suggested cutoff values 
found in studies on clinical pain, and the pain stimulation used here is one of the most common methods in 
experimental pain  studies38. The use of cutoff values for pain changes to perform responder analyses has been 
recommended for clinical pain trials with the reasoning that statistical mean differences might not capture the 
experienced effect of pain reductions in most  patients39–41. Thus, the definition of placebo responders versus 
nonresponders based on cutoffs could be a beneficial add-on for analyses for both clinical and experimental 
studies. However, the terms “placebo responders and nonresponders” does not imply that participants who 
shows a positive response to placebo administration in e.g., a pain study will be placebo responders in other 
situations. Placebo responding and placebo nonresponding are probably not consistent  traits14,42, but depend on 
the individual learning history of the  participants43, level of emotional activation during  treatment44, and genetic 
 factors20,45 associated with the sensory modality in which the placebo treatment is used.
The magnitude and impact of placebo analgesic effects in clinical trials and experimental studies have been 
debated, e.g.,12,31,46,47. Nonetheless, these meta-analyses have shown that placebo administration has a statistical 
impact on self-reported pain. Furthermore, Zunhammer et al.48,49 found in meta-analyses that placebo admin-
istration has minor effects on the neurologic pain  signature50 but moderate effects on pain reports, which sug-
gests that the measurement and analysis of pain reports are crucial for determining the magnitude of placebo 
analgesic effects. Nevertheless, most meta-analyses have not analyzed whether the observed effects of placebos 
had a clinically meaningful impact. To date, the only meta-analysis that tested clinical significance in relation to 
placebo analgesia found that the placebo analgesic effect was higher in patients than in healthy controls in terms 
of clinically significant reductions in pain when using the reduction criteria of ≥ 13  mm7 on a 0–100 VAS or NRS 
 scale12. Interestingly, meta-analyses that have used effect sizes as the main outcome measure have shown the 
opposite finding: the placebo effect is larger in healthy controls than in  patients31,32. Taken together, analyses of 
placebo effects in future studies should preferably include assessments of both statistical and clinical significance, 
at least in studies making inferences about patient-reported outcomes such as  pain51.
The present study shows that placebo responders can be separated from nonresponders with a straightforward 
procedure based on unsupervised cluster analysis and cutoffs selected by logistic regression implemented in 
machine learning. These statistical tools are available in several statistical software packages and could easily be 
used by scientists with some experience in statistics. Moreover, the machine learning application used here can 
be replaced by an ROC curve analysis providing data for sensitivity and  specificity52 that is implemented in most 
statistical programs or software specialized for finding optimal cutoff  points53. However, the latter does require 
that the patients/participants be classified as either responders or nonresponders before the analysis to find the 
optimal cutoff is performed. Thus, in cases where there is no diagnostic information or clinical classification, an 
unsupervised cluster analysis may help the categorization process without inducing bias associated with manual 
human classification. The two-cluster classification of the placebo responses of the present study was replicated in 
other data from our lab. However, other types of experimental designs may provide more complex classification 
of  responses54. In data where more than two clusters are found, the logistic regression and eventually the Youden 
index must be replaced with classification analyses that handle multiclass data such as support vector machines 
or similar methods. An advantage of machine learning algorithms for classification over standard statistical 
methods is that these applications provide additional statistics, such as FDR values, compared to other analysis 
such as logistic regression. Furthermore, the flexibility in model specifications, such as validation schemes of the 
selected model, provides better control over the accuracy and error rate compared to standard statistical methods.
Methods
Data from 296 healthy subjects who participated in an experimental study on genetic factors in placebo 
 analgesia20 were used for the present analyses. The characteristics of the sample are described in detail in previ-
ous  publications20,55.
The participants were randomized into three groups: (1) a placebo group (N = 155) that received a mois-
turizing cream with no analgesic properties (E-45; Crookes Healthcare, Nottingham, United Kingdom), (2) a 
natural history group (N = 141) that received no treatment during the procedure, or (3) a lidocaine-prilocaine 
cream group (N = 31) that received a local anesthetic cream (Emla; AstraZeneca, Oslo, Norway)20. Thus, the 
study included a total of 327 healthy participants with a mean age of 23 years (SD = 3.3). A dose of 3 g of Emla or 
E-45 was used for each participant. The group receiving the anesthetic cream was used in the design to ensure 
blinding of the experimenters, and these data were not used in the  analyses20,55. The experiment was run in a 
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double-blind manner for the groups where a cream was applied, but there was no blinding in the natural his-
tory group. Randomization was performed before the start of the experiment. The participants were allocated 
to the different groups based on their participant number. The participant numbers and group allocations were 
randomized by using the online web service https:// www. random. org/ lists/. Thirty-one of the participants were 
randomized into the lidocaine-prilocaine cream group. Hence, data from 296 participants were included in 
the final  analyses20. The study was reviewed and approved by the Regional Committee for Medical and Health 
Research Ethics, Region Northern Norway (project number 23430), and the study was performed in accordance 
with The Declaration of Helsinki. All participants signed an informed consent before participation. In the consent 
form, they stated that they had no history of ongoing disease or any history of serious disease.
Design and stimuli. The study was designed as a repeated measures design with a calibration phase for 
determination of temperatures that invoked pain corresponding to 60 mm on a 100-mm computerized visual 
analog scale (VAS) scale. Thermal stimuli to the left underarm were delivered by a computer-controlled ther-
mode (Pathway, Medoc, Israel) to induce heat pain. To ensure an equal pain level across participants at the start 
of the experiment, a calibration procedure was performed. To approximate the stimulus intensity needed to 
produce a rating of 60 on the VAS, Stevens power  equation56 was used to produce a stimulus–response func-
tion for estimation of the individual target temperature of the thermode. After the calibration phase, the pretest 
consisting of the presentation of two pain stimuli was performed. The duration of the stimulations in the pretests 
and posttests was 10 s from when the thermode reached the calibrated target temperature (43–47 °C) until the 
start of the return to baseline at 32 °C20,55. The temperature of the thermode increased/decreased by 10 °C/s. The 
interval between the two pretests was 30 s. The two posttests had the same temperature, duration, and intervals 
as the  pretests20,55. Directly after the pretests, information about the treatment was provided to the participants 
allocated to the groups that received either placebo or  Emla20,55. The participants in the placebo group were told 
“The cream that will be applied to your arm reduces pain, the substance in the cream is used as a local anesthetic 
in many pain-reducing remedies and is effective in the treatment of heat pain.” The participants in the natural 
history group received no application of cream and were told that they could relax in the break between the 
pretests and the  posttests20,55. The experimental procedure had a total duration of approximately 45 min, which 
included saliva sampling for genetic analyses and measurements of blood pressure and subjective stress.
Statistical analyses. A two-step cluster analysis in SPSS v. 26 (SPSS, IBM, USA) was used to classify 
changes in VAS pain intensity from the pretest to the posttest. The order of the participants in the datafile 
was randomized by the randperm function in MATLAB (MATLAB v.R2019b, Sweden). The cluster analysis 
was set to automatically determine the optimal number of clusters by using Schwarz’s Bayesian  criterion57 and 
log-likelihood as the distance measure https:// www. ibm. com/ suppo rt/ knowl edgec enter/ SSLVMB_ 24.0. 0/ spss/ 
base/ idh_ twost ep_ main. html . The quality of the cluster analysis was measured by the silhouette coefficient, 
which is a measure of both cohesion and separation of the suggested clusters. MATLAB Classification Learner 
(MATLAB, Sweden; https:// se. mathw orks. com/ help/ stats/ class ifica tionl earner- app. html) with cross-validation 
(fivefolds) was used for the prediction of cutoff values from the two-step cluster analysis. The logistic regression 
classifier was used for classification of the selected possible cutoffs for the absolute VAS change and percentage 
change between the pre- and posttests. The possible cutoffs were tested separately. Predictive values were deter-
mined from ROC curves providing area under the curve (AUC) values and a confusion matrix that provided 
false discovery rate (FDR) values. The accuracy of the predictor is in the Classification Learner calculated from 
the cross-validation. The Youden index was calculated in SPSS based on a script (https:// www. ibm. com/ suppo 
rt/ pages/ can- spss- produ ce- youde ns- index). Group comparisons were performed with two-tailed t-tests. p val-
ues < .05 were considered significant.
Data availability
All data used in the analyses for this article can be found at https:// datav erse. no/.
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